Management of oral reactions from immune checkpoint inhibitor therapy: A systematic review - 10/10/20
Doi : 10.1016/j.jaad.2020.05.133
Nirav Shah, BA a, Leah Cohen, MD b, Lucia Seminario-Vidal, MD, PhD c, d, ⁎ 
a Morsani College of Medicine, University of South Florida, Tampa, Florida
b Herbert Wertheim College of Medicine, Florida International University, Miami, Florida
c Department of Dermatology, University of South Florida, Tampa, Florida
d Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida
∗Correspondence to: Lucia Seminario-Vidal, MD, PhD, 13330 USF Laurel Dr, 6th Floor, Tampa, FL 3361213330 USF Laurel Dr, 6th FloorTampaFL33612
| Funding sources: None. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 5
P. 1493-1498 - novembre 2020 Retour au numéro
Article précédent
- Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia
- Abhijeet Kumar Jha, Sidharth Sonthalia, MD Zeeshan, Keshavamurthy Vinay
- Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials
- Marjolein de Bruin-Weller, Eric L. Simpson, Michael Cork, Zhen Chen, Jerome Msihid, Christine Taniou, Laurent Eckert, Abhijit Gadkari, Gaëlle Bégo-Le Bagousse
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?